Celon Pharma S.A.

Warsaw Stock Exchange CLN.WA

Celon Pharma S.A. Cash and Short-Term Investments for the year ending December 31, 2023: USD 29.05 M

Celon Pharma S.A. Cash and Short-Term Investments is USD 29.05 M for the year ending December 31, 2023, a -22.69% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Celon Pharma S.A. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 37.57 M, a -33.25% change year over year.
Celon Pharma S.A. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 56.29 M, a 378.09% change year over year.
Celon Pharma S.A. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 11.77 M, a -32.91% change year over year.
Celon Pharma S.A. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 17.55 M, a -55.58% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Warsaw Stock Exchange: CLN.WA

Celon Pharma S.A.

CEO	Dr. Maciej Wieczorek Ph.D.
IPO Date	Feb. 17, 2017
Location	Poland
Headquarters	ul. Ogrodowa
Employees	566
Sector	Healthcare
Industries Pharmaceuticals Biotechnology

Description

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.

Key trends

Past 5 years